Tolerable treatments lacking for higher-risk myelodysplastic syndromes
There is a clear, unmet need for tolerable treatments that can produce durable remission among patients with higher-risk myelodysplastic syndromes (HR-MDS), according to a study published online Sept. 7 in Leukemia & Lymphoma.
Oct 20, 2023
0
0